Oleylphosphocholine versus Miltefosine for Canine Leishmaniasis

Area of Science:

• Veterinary Medicine
• Parasitology
• Pharmacology

Background:

• Canine leishmaniasis is a significant concern, impacting both animal health and serving as a model for human clinical development.
• Miltefosine is an approved treatment, but derivatives like Oleylphosphocholine (OlPC) are being investigated for improved efficacy.

Purpose of the Study:

• To compare the efficacy of Oleylphosphocholine (OlPC) against the standard miltefosine treatment in dogs naturally infected with Leishmania.
• To evaluate the clinical outcomes and parasite burden following treatment with OlPC versus miltefosine.

Main Methods:

• A randomized controlled trial involving 33 naturally infected dogs, comparing OlPC (4 mg/kg/day) with miltefosine (2 mg/kg/day) for 28 days.
• Clinical parameters were assessed using a standardized scoring system by a blinded observer over a 5-month post-treatment follow-up period.

Main Results:

• Oleylphosphocholine (OlPC) treatment resulted in significantly lower mean clinical scores at 3 and 5 months post-therapy compared to miltefosine (P <0.01).
• OlPC group showed statistically significant reductions in lymph node size, ear crusting, and splenic parasite load.
• One case of kidney failure in the OlPC group was noted, potentially linked to pre-existing immune-complex deposition, warranting further investigation.

Conclusions:

• Oleylphosphocholine (OlPC) demonstrates superior clinical efficacy compared to miltefosine in treating canine leishmaniasis.
• The improved outcomes suggest OlPC's potential as a more effective oral therapeutic for both canine and human leishmaniasis.